Thanks for posting the information, its interesting to see that it has happened in the past, such as with Questcor, but not alot thankfully.

I think though this would not happen with LL for two reasons--there is plenty of trial data showing LL's effectiveness, both in trials and right to try, and 2. works in synergy with current products, not in competition. Why would any company shelve a product that just makes their current lineup more effective and valuable?

Don't get me wrong, this does not forget that LL can in some indications act as a competitor, but if it also enhances another company's product that brings value to their product, there is no way they would buy it to shelve it they can either bring value to their current pipeline or add a new revenue stream.

IMO